Recent studies have demonstrated that small double-stranded RNAs (dsRNAs) complementary to the promoter region of target genes enhance the expression of those genes following transfection into cells. Here we show that expression of the matrix metalloproteinase (MMP) inhibitor RECK is activated in the cultured tumor cell lines by transfection with dsRNA complementary to the promoter of the RECK gene, leading to suppression of the expression of MMPs and it inhibited tumor cell invasion. These results support the suggestion that dsRNA complementary to the promoter region of tumor suppressor genes would have potential as a novel antitumor agent.
INTRODUCTION
Recently, much attention has been focused on RNA interference (RNAi) because small interfering RNA (siRNA), which is perfectly complementary to target mRNA, efficiently and specifically suppresses the expression of target genes. Following the introduction of siRNA into cells, siRNA is incorporated into the RNA-induced silencing complex, which consists of argonaute 2 (Ago2) as a main component, and subsequently binds to the complementary sequence in the target mRNA, resulting in the cleavage of target mRNA by the slicer activity of Ago2. At the present time, siRNAs are not only widely used as research tools for gene function analysis but have also being entered into human clinical trials as possible therapeutic agents for various types of diseases, including cancer and infectious diseases. The expression of target genes can also be suppressed at the transcriptional step by B21 nt small double-stranded RNA (dsRNA) complementary to the promoter region of target genes. [1] [2] [3] [4] [5] [6] This phenomenon is designated as transcriptional gene silencing. Although the detailed mechanism of transcriptional gene silencing has not been fully elucidated, the expressions of several genes, including the human progesterone receptor, 1 c-myc, 5 and ubiquitin C genes, 6 have been shown to be suppressed by transcriptional gene silencing.
On the other hand, several studies have reported that the expression of target genes can be upregulated at the transcriptional level by B21 nt dsRNA complementary to the promoter region of target genes. [7] [8] [9] [10] [11] [12] The transcriptional activation of target genes by promoter-targeted dsRNAs is often designated as RNA activation (RNAa). RNAa seems highly promising for therapeutic application, since therapeutic benefit is often obtained by upregulation of target gene expression. Given that promotertargeted dsRNAs efficiently activate the expression of target genes, promoter-targeted dsRNAs would have great potential as therapeutic agents, much like siRNAs. Several genes have already been shown to be activated by RNAa, including E-cadherin, 13 progesterone receptor, 7 and low-density-lipoprotein receptor genes; 8 however, the therapeutic potential of RNAa has not been fully evaluated.
In this study, we examined whether expression of the RECK gene, which is a transformation suppressor gene, was activated by transfection with promoter-targeted dsRNAs in cultured tumor cells in order to exploit dsRNAs inducing RNAa as a potential antitumor agent in cancer therapies. RECK is a membraneanchored glycoprotein that inhibits matrix metalloproteinases (MMPs) and suppresses tumor metastasis and angiogenesis. [14] [15] [16] Although RECK mRNA is expressed in most normal cells, it frequently shows extremely low or no expression in tumor cell lines and cancer tissues. Therefore, we considered that promotertargeted dsRNA-mediated upregulation of the RECK gene should result in inhibition of MMPs and tumor invasion. This study demonstrated that activation of RECK gene expression was achieved by transfection with promoter-targeted dsRNA, leading to suppression of MMPs and invasion of tumor cells.
MATERIALS AND METHODS

Cells and promoter-targeted dsRNAs
MDA-MB-231 cells (a human breast cancer cell line), A549 cells (a human lung adenocarcinoma cell line), and H1299 cells (a human non-small lung carcinoma cell line) were cultured with Dulbecco's modified Eagle Medium supplemented with 10% fetal calf serum (FCS) and antibiotics in a humidified atmosphere of 5% CO 2 at 37 1C. dsRNAs, which were 19-base pair RNA duplexes with 2-base deoxythymidine overhangs at the 3 0 ends, were purchased from Genedesign (Osaka, Japan). AllStars negative control siRNA (QIAGEN, Valencia, CA, USA) was used as a control dsRNA.
Analysis of transcriptional start sites (TSS) of the RECK gene Rapid amplification of complementart DNA (cDNA) end (RACE) analysis was carried out using a GeneRacer kit (Invitrogen, Carlsbad, CA, USA) in order to examine the transcriptional start sites of the RECK gene. cDNA samples from MDA-MB-231 cells and A549 cells were prepared according to the manufacturer's instruction. The 5 0 end of cDNA was amplified through two nested PCR steps using KOD-plus (Toyobo, Osaka, Japan). After gel purification, the PCR products were cloned using a TOPO TA cloning kit (Invitrogen) and sequenced.
Transfection with promoter-targeted dsRNAs Cells were seeded in a 24-or 6-well plate at a density of 2.5 Â 10 4 cells cm
. On the following day, dsRNAs were transfected at the various concentrations into cells using Lipofectamine RNAiMAX (Invitrogen). The medium containing the dsRNAs was replaced with fresh medium containing 10% FCS 24 h after transfection. Following a total 72-h (for realtime RT-PCR analysis) or a 96-h incubation (for western blotting analysis), the cells were recovered from the plate for analysis of RECK expression.
Western blotting analysis
Cells were washed with phosphate-buffered saline (PBS) 4 days after transfection with dsRNAs as described above and lysed with lysis buffer (20 mM Hepes, 2 mM EGTA, 10% glycerol, 1% Triton-X, 1 mM DTT, and protease inhibitor cocktail). The lysates were centrifuged at 15 100 g for 15 min, and the protein concentrations in each lysate were measured using a Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Hercules, CA, USA). The lysates were electrophoresed on sodium dodecyl sulphate-polyacrylamide gel. The proteins were transferred to polyvinylidene difluoride membranes and immunoblotted with monoclonal anti-RECK antibody (clone 28; BD Biosciences, San Jose, CA, USA) and polyclonal anti-b-tubulin antibody (Abcam, Cambridge, UK). The bands were visualized and analyzed by using an ECL Plus detection kit (GE Healthcare, Buckinghamshire, UK) and LAS-3000 imaging system (Fujifilm, Tokyo, Japan), respectively.
Real-time RT-PCR analysis
Following transfection with dsRNAs, total RNA from the cells was extracted using Isogen (Nippon Gene, Tokyo, Japan). RNA was treated with DNaseI to digest the genomic DNA, and 1 mg RNA was reverse-transcribed using a SuperScript II First-Strand Synthesis System (Invitrogen). The RECK and MMP-9 mRNA levels were determined using real-time RT-PCR and normalized with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels. Real-time RT-PCR was performed with SYBR Premix Ex Taq II (TaKaRa, Otsu, Japan) using an ABI StepOnePlus (Applied Biosystems, Foster City, CA, USA). The oligonucleotide primer pairs were designed as follows: RECK forward, 5 0 -AGTGCGGGTGCATTGTGTT-3 0 ; RECK reverse,
Pretreatment with siRNA against Ago1 and Ago2
MDA-MB-231 cells were seeded as described above. On the following day, the cells were transfected with siRNA against Ago1 (siAgo1) and Ago2 (siAgo2) at 100 nM. The medium containing siRNA was replaced with fresh medium 24 h after transfection. RECK-82 and control dsRNA were transfected into the cells at 100 nM 48 h after siRNA transfection. Total RNA was recovered for real-time RT-PCR analysis 3 days after transfection with RECK-82 and control dsRNA. Real-time RT-PCR analysis was performed as described above. The targeted sequences of siAgo1 and siAgo2 are as follows: siAgo1, 5 0 -gagaagaggugcucaagaauu-3 0 ; siAgo2, 5 0 -gcacggaaguccaucugaa-3 0 .
Gelatin zymography assay
Cells were transfected with the dsRNAs at 100 nM as described above. The culture medium was exchanged for serum-free medium 72 h after transfection and incubated for 24 h. The conditioned media were collected and centrifugated at 15 100 g for 15 min. Gelatin zymography assay was performed using a Gelatin Zymo-Electrophoresis Kit (Primary Cell, Sapporo, Japan) according to the manufacturer's directions. Briefly, 10 ml of the conditioned media was mixed with 10 ml of sample preparation buffer and were incubated for 15 min at room temperature. Samples were applied to the gels, followed by electrophoresis for 2 h. The gels were then washed by Small RNA-mediated upregulation of target genes F Sakurai et al incubating in the wash buffer for 30 min after electrophoresis, and incubated in the reaction buffer at 37 1C for 40 h for enzymatic reaction, followed by staining the gels with the staining buffer. The images of gels were taken using LAS4010 (Fujifilm) after destaining of the gels.
In vitro tumor cell invasion assay
Following transfection with the dsRNAs at 100 nM, MDA-MB-231 cells were recovered from the plate and then re-seeded into the upper chamber of a BD MioCoat Matrigel Invasion Chamber (BD Bioscience) in serum-free medium. The cells were allowed to invade into the bottom chamber containing 10% FCS for 24 h. Non-invading cells on the upper surface of the membrane were wiped off with a cotton swab, and the cells that had invaded to the lower surface of the membrane were fixed and stained with 4 0 ,6-diamidino-2-phenylindole (DAPI). Invasiveness was determined by counting cells in four microscopic fields per well.
Statistical analysis
Statistical significance was tested by paired t-test for direct two-group comparisons.
RESULTS
Design of dsRNAs targeting the promoter region of the RECK gene
In order to design promoter-targeted dsRNAs that upregulate RECK gene expression following transfection, the transcriptional start site (TSS) of the RECK gene was first examined by 5 0 RACE analysis. In previous studies, RNAa was observed by transfection with dsRNAs complementary to the genomic region upstream of TSS. [7] [8] [9] [10] [11] [12] [13] We sequenced 19 and 22 clones of 5 0 RACE products for the RECK gene in MDA-MB-231 and A549 cells, and identified six TSSs in MDA-MB-231 cells and two TSSs in A549 cells (Figure 1 ). These TSSs identified by 5 0 -RACE analysis were located downstream of that in the database for the transcriptional start site (http://dbtss.hgc.jp/). In this study, the TSS in the Database for Transcriptional Start Sites was designated as þ 1. Based on the data of TSS described above, eight dsRNAs perfectly complementary to the promoter region of the RECK gene were designed ( Figure 1 , Table 1 ). These promoter-targeted dsRNAs did not possess the sequence complementary to RECK mRNA. Promotertargeted dsRNAs were designed to lower the G þ C content of Small RNA-mediated upregulation of target genes F Sakurai et al dsRNAs as much as possible (G þ C content of promoter-targeted dsRNAs; 47-63%). We did not follow the other favorable criteria for effective siRNA design previously proposed, 17 except for C þ G content.
Activation of RECK gene expression by promoter-targeted dsRNAs Next, in order to examine whether the promoter-targeted dsRNAs activate RECK gene expression following transfection in tumor cells, RECK expression levels in MDA-MB-231 cells were determined using real-time RT-PCR and western blotting analysis. Western blotting analysis demonstrated that RECK-82 upregulated RECK protein levels most efficiently among the promoter-targeted dsRNAs examined (Figure 2a ). An almost 2.5-fold increase in the RECK protein level was found following transfection with RECK-82, compared with the mock-transfected group (Figure 2b) . RECK-82 also induced a statistically significant increase (B1.6-fold) in RECK mRNA levels following transfection in MDA-MB-231 cells (Figure 2c) . Although RECK-128 and RECK-43 induced RECK mRNA production at levels similar to that by RECK-82, no apparent increase in RECK protein levels was found for either RECK-128 or RECK-43 on day 4 (Figure 2b ) or other day points (data not shown). RECK-82-mediated upregulation of RECK protein and mRNA levels was also found in A549 and H1299 cells, although RECK protein and mRNA levels were slightly increased by control siRNA in H1299 cells (Figures 2d and e) . These results indicate that RECK expression can be activated by promoter-targeted dsRNAs and that RECK-82 is the most efficient promoter-targeted dsRNA for activation of RECK gene expression. No apparent cellular toxicities were found in any of the cells tested following transduction with the dsRNAs (data not shown).
Properties of promoter-targeted dsRNA-mediated activation of RECK gene expression Next, analyses on the time course and dose-dependency of promoter-targeted dsRNA-mediated upregulation of RECK protein levels were performed. RECK-82-mediated upregulation in RECK protein levels were found 3 days after transfection, and peaked 4 days after transfection in MDA-MB-231 cells (Figure 3a) . Thereafter, the RECK protein levels were gradually reduced, but higher levels of RECK protein levels were still found 8 days after transfection, compared with that in the cells transfected with control dsRNA. RECK protein levels were increased by RECK-82 at concentrations as low as 6 and 1 nM in MDA-MB-231 and A549 cells, respectively (Figures 3b and c) .
In order to examine whether sequence complementarity of the dsRNAs to the RECK promoter region is crucial for the upregulation of RECK gene expression by RECK-82, mismatch-containing dsRNAs (RECK-82 mm1 and RECK-82 mm2) and scrambled dsRNAs (RECK-82sc1 and RECK-82sc2) were designed based on the sequence of RECK-82 (Table 1) , and introduced into cells. RECK-82-mm1 and RECK-82 mm2 contain four mismatches. No significant increase in RECK protein levels was observed following transfection with the mismatched or scrambled dsRNAs (Figure 3d ), indicating that sequence complementarity of dsRNAs is indispensable for promoter-targeted dsRNA-induced upregulation of RECK expression.
Next, in order to investigate whether interferon (IFN) responses induced by promoter-targeted dsRNAs are involved in upregulation of RECK gene expression, the mRNA levels of IFN-stimulated genes (ISG) were determined by real-time RT-PCR following transfection. Induction of type I IFN production by dsRNAs often causes off-target effects. The mRNA levels of ISG15 and 56, which are upregulated by type I IFN, were slightly increased by control dsRNA and RECK-82 (less than threefold increase); however, the mRNA levels of ISG15 and 56 were comparable between control dsRNA and RECK-82 (Figures 4a and b) . In addition, transfection with poly I:C, which is a strong type I IFN inducer, did not mediate upregulation of RECK mRNA levels at 3 days following transfection (Figure 4b ). These results indicate that upregulation of RECK gene expression by RECK-82 is not due to type I IFN induction.
In order to examine whether Ago 1 and 2 are involved in RECK-82-induced upregulation of RECK expression, RECK-82 was transfected into MDA-MB-231 cells following siRNA-mediated knockdown of Ago1 or Ago2. Previous studies demonstrated that Ago1 and Ago2 were involved in promoter-targeted dsRNAmediated upregulation of target gene expression. 9, 18 mRNA levels of Ago1 and Ago2 were almost fivefold reduced by siRNA, compared with control dsRNA, 24 h after transfection (Figure 5a ). Knockdown of Ago1 or Ago2 did not reduce RECK-82-induced upregulation of RECK mRNA levels, but rather the averages of RECK mRNA levels were slightly increased (Figure 5b ). These (Figure 7a ). An approximately sevenfold reduction in the number of tumor cells invading into the transwell chamber was observed for RECK-82 (Figure 7b ). These results indicate that RECK-82-induced activation of RECK expression leads to a suppression of tumor cell invasion, probably via an inhibition of MMP.
DISCUSSION
The aim of this study was to evaluate the potential of RNAainducing dsRNAs for therapeutic applications. Previous studies have reported that several genes can be upregulated following transfection with promoter-targeted dsRNAs; [7] [8] [9] [10] [11] 13, 20 however, therapeutic potential of promoter-targeted dsRNAs has not been fully demonstrated, especially for treatment of cancer. Promotertargeted dsRNA-induced RNAa appears highly suitable for therapeutic application because treatment of diseases can often be achieved by upregulating the expression of target genes. Furthermore, the activation of target gene expression is highly Small RNA-mediated upregulation of target genes F Sakurai et al sequence-specific and continues for B1 week or longer following transfection with promoter-targeted dsRNAs. 7, 8 Chemically modified dsRNAs, which are resistant to RNase-mediated degradation, also mediate RNAa with an efficiency comparable to conventional promoter-targeted dsRNAs. 8, 21 Recently, in vivo application of RNAa has been reported. 22, 23 Continued research into the therapeutic applications of RNAa is warranted and expected.
In this study, the RECK gene was selected as a target gene of RNAa for the following reasons. First, RECK efficiently regulates extracellular matrix integrity and angiogenesis in the tumor cells by inhibiting members of the MMP family. Previous studies demonstrated that overexpression of RECK in the tumor cells significantly inhibited the expression and activity of MMPs, leading to the suppression of tumor invasion and metastasis. 14, 15 These results led us to hypothesize that RNAa-mediated upregulation of RECK leads to the suppression of tumor invasion and metastasis. Second, RECK is often downregulated in tumor cells. Janowski et al. 7 demonstrated that efficient upregulation of target gene expression was found by RNAa when the basal expression level of the target gene was relatively low. Third, RECK expression is epigenetically silenced in tumor cells. 24, 25 Loss of RECK gene expression or RECK activity by genetic mutation in the RECK gene has not been reported. Tumor suppressor genes, including the p53 gene, would seem to be promising genes for RNAa; however, the tumor suppressor genes in the tumor cells and tissues often possess mutations that reduce or block their activity. In such cases, therapeutic effects would not be obtained even if RNAa-mediated upregulation of the tumor suppressor genes occurred. Nonetheless, tumor suppressor genes that fulfill the criteria described above would be a promising target for RNAamediated cancer therapy.
In the previous studies on RNAa, several cellular factors have been demonstrated to be involved in RNAa. Schwartz et al. 26 reported that non-coding transcripts that are transcribed from the promoter region of the target gene are targets for promotertargeted dsRNAs inducing RNAa. Non-coding transcripts transcribed from the promoter region were also detected in other genes that can be upregulated by RNAa. 8, 27 We performed RT-PCR analysis to detect non-coding transcript from the promoter region of the RECK gene; however, a detectable level of non-coding transcript was not transcribed from the promoter region of the RECK gene. In addition, Ago1 and Ago2 had an important role in RNAa-induced upregulation of the progesterone receptor, 18 low density lipoprotein receptor, 8 and p21 genes. 13 siRNA-mediated knockdown of Ago1 or Ago2 reduced the promoter-targeted dsRNA-mediated upregulation of the target genes. However, activity of RECK-82 was unaffected by Ago1 or Ago2 knockdown in this study. These results suggest that the mechanism of promoter-targeted dsRNA-mediated upregulation of the RECK gene would be somewhat different from that of the other genes described above. Viral and non-viral gene delivery vehicles are often used for introduction and overexpression of foreign genes. RNAa might become a promising alternative to gene delivery because there are various obstacles in the vector-mediated delivery of foreign genes, including inefficient delivery of foreign genes and immunogenicity of gene delivery vectors; however, in general, RNAa expresses target genes at much lower levels than gene delivery. More efficient induction of target gene expression should be required for the therapeutic application of promoter-targeted dsRNA-induced RNAa.
In summary, this study demonstrated that RECK expression was upregulated by transfection with dsRNA complementary to the promoter region of the RECK gene in the cultured cell lines. Promoter-targeted dsRNA-mediated upregulation of RECK expression was sequence-dependent and was seen until 8 days after transfection. Promoter-targeted dsRNA-mediated upregulation of RECK expression resulted in the suppression of MMP expression and activities, leading to the inhibition of tumor cell invasion. These findings support the suggestion that RNAa-inducing dsRNAs have great potential for therapeutic applications, although further investigation will be needed.
